FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application
S&P Animal Health Partnering Oct 2023 S&P Animal Health Partnering Oct 2023 Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
New treatment for chronic kidney disease approved in the EU New treatment for chronic kidney disease approved in the EU The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Results for Jardiance EMPACT-MI phase III trial Results for Jardiance EMPACT-MI phase III trial Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Full data chronic kidney disease trial efficacy Full data chronic kidney disease trial efficacy Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy